NDA 050795 · Mayne Pharma
Doryx Mpc
Doxycycline Hyclate · Oral
Last checked: Nov 19, 2026Latest source record: Mar 31, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
May 6, 2005
Approved uses
5
Original approval plus efficacy supplements
Registered trials
424
81 Phase 3, 42 recruiting
FAERS reports
17,469
10,251 serious, 2,363 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 16, 2026.
DORYX MPC is a tetracycline class drug indicated for: Rickettsial Infections ( 1.1 ) Sexually Transmitted Infections ( 1.2 ) Respiratory Tract Infections( 1.3 ) Specific Bacterial Infections ( 1.4 ) Ophthalmic Infections ( 1.5 ) Anthrax, Including Inhalational Anthrax (Post-Exposure) ( 1.6 ) Alternative Treatment for Selected Infections when Penicillin is Contraindicated ( 1.7 ) Adjunctive Therapy in Acute Intestinal Amebiasis and Severe Acne ( 1.8 ) Prophylaxis of Malaria ( 1.9 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline hyclate and other antibacterial drugs, DORYX MPC Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.10 ) 1.1 Rickettsial Infections DORYX MPC is indicated for treatment of Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . 1.2 Sexually Transmitted Infections DORYX MPC is indicated for treatment of the following sexually transmitted infections: Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum . Lymphogranuloma venereum caused by Chlamydia trachomatis . Granuloma inguinale caused by Klebsiella granulomatis . Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Chancroid caused by Haemophilus ducreyi . 1.3 Respiratory Tract Infections DORYX MPC is indicated for treatment of the following respiratory tract infections: Respiratory tract infections caused by Mycoplasma pneumoniae . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Because many strains of the following groups of microorganisms have been shown to be...
Mechanism: Doxycycline is a tetracycline-class antimicrobial drug [ see Microbiology (12.4) ].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 31, 2017 Supplement 24 · Efficacy LabelLetter
- May 20, 2016 Supplement 22 · Efficacy LabelReviewLetter
- Apr 11, 2013 Supplement 10 · Efficacy · priority review Pediatric Clinical Pharmacology ReviewPediatric Statistical ReviewPediatric Medical Review
- Dec 19, 2006 Supplement 2 · Efficacy LabelLetter
- May 6, 2005 Original approval · Type 3 - New Dosage Form LabelReviewLetter
8 products under this application
- DORYX MPC · DOXYCYCLINE HYCLATE EQ 120MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, DELAYED RELEASE, ORAL · Discontinued
- DORYX · DOXYCYCLINE HYCLATE EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, DELAYED RELEASE, ORAL · Discontinued · TE AB
- DORYX · DOXYCYCLINE HYCLATE EQ 80MG BASE · TABLET, DELAYED RELEASE, ORAL · Discontinued · TE AB
- DORYX · DOXYCYCLINE HYCLATE EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, DELAYED RELEASE, ORAL · Discontinued · TE AB
- DORYX MPC · DOXYCYCLINE HYCLATE EQ 60MG BASE · TABLET, DELAYED RELEASE, ORAL · Prescription · TE AB
- DORYX · DOXYCYCLINE HYCLATE EQ 200MG BASE · TABLET, DELAYED RELEASE, ORAL · Discontinued · TE AB
- DORYX · DOXYCYCLINE HYCLATE EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, DELAYED RELEASE, ORAL · Discontinued · TE AB
- DORYX · DOXYCYCLINE HYCLATE EQ 75MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, DELAYED RELEASE, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Doxycycline Hyclate" as an intervention, any sponsor and status, largest first.
- Antibiotic Prophylaxis in High-Risk Arthroplasty PatientsPivotal-lookingEnrolling by invitation
Mayo ClinicAcademic, hospital or other
NCT04297592 · 4,618 participants (planned) · Start Jun 11, 2020 · Primary completion Jan 2027
Drug: Cephalexin; Doxycycline and 1 more · For: Infections Joint Prosthetic; Overweight or Obesity; MSSA Colonization and 6 more
Sites: Iowa City, Iowa; Rochester, Minnesota
- Helicobacter Pylori Eradication and Follow-upStatus unknown
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT05061732 · 4,447 participants (planned) · Start Sep 30, 2021 · Primary completion Jun 30, 2026
Drug: Rabeprazole; Bismuth potassium citrate and 7 more · For: Helicobacter Pylori Infection
Sites: Shanghai, China
- Periodic Presumptive Treatment vs. doxyPEP for STI Control in Kenyan MSMPivotal-lookingActive, not recruiting
University of WashingtonAcademic, hospital or other
NCT06468462 · 2,900 participants (planned) · Start Oct 29, 2025 · Primary completion Oct 31, 2028
Drug: WHO-recommended periodic presumptive treatment; Doxycycline post-exposure prophylaxis · For: Gonorrhea Male; Chlamydia (Male); Syphilis Male
Sites: Kisumu, Kenya; Mombasa, Kenya; Nairobi, Kenya
- To Compare the Strategies of Universal Antibiotic Prophylaxis Versus Screen-and-treat in Reducing Infective Complications and Re-infection in Women Who Undergo Termination of PregnancyPivotal-lookingCompleted
The University of Hong KongAcademic, hospital or other
NCT01842100 · 2,193 participants · Start Sep 1999 · Primary completion Feb 2006
Drug: Universal antibiotic prophylaxis · For: Induced Abortion; Postaboral Pelvic Inflammatory Disease; Sexually Transmitted Infections
Sites: Hong Kong, China
- The Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolPivotal-lookingCompleted
The Camelot FoundationAcademic, hospital or other
NCT04349410 · 1,800 participants · Start Apr 11, 2020 · Primary completion Sep 14, 2020
Drug: Hydroxychloroquine, Azithromycin; Hydroxychloroquine, Doxycycline and 9 more · For: CoVid 19 Positive
Sites: Los Angeles, California
- AUTOP 2: Screen-and-treat Strategy for Vaginal Flora Abnormalities by Molecular Biology in Pregnant Women at High Risk of Preterm BirthPivotal-lookingNot yet recruiting
Assistance Publique Hopitaux De MarseilleAcademic, hospital or other
NCT06349122 · 1,794 participants (planned) · Start Oct 2026 · Primary completion Jun 2029
Drug: Azithromycin; Ceftriaxone and 3 more · For: Bacterial Vaginosis; Vaginal Dysbiosis; Premature Delivery
- Doxycycline to Treat Mansonella Perstans Infection in Patients With and Without Lymphatic FilariasisCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00340691 · 1,500 participants · Start Dec 6, 2004 · Primary completion Oct 4, 2007
Drug: Doxycycline · For: Mansonella Perstans Infection; Mp Microfilaremia
Sites: Bethesda, Maryland
Galderma R&DIndustry
NCT00892281 · 1,421 participants · Start Apr 2009 · Primary completion Oct 2009
Drug: doxycycline (Oracea®) 40 mg modified release as monotherapy; doxycycline (Oracea®) 40 mg modified release as add-on therapy · For: Rosacea
Sites: Lexington, Kentucky
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug hypersensitivity2,304
- fatigue1,817
- nausea1,715
- pain1,489
- rash1,463
- off label use1,432
- drug ineffective1,415
- headache1,402
- diarrhoea1,371
- dyspnoea1,349
- vomiting1,339
- pruritus1,166
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 15 |
| 2005 | 14 |
| 2006 | 23 |
| 2007 | 25 |
| 2008 | 36 |
| 2009 | 88 |
| 2010 | 107 |
| 2011 | 142 |
| 2012 | 255 |
| 2013 | 251 |
| 2014 | 341 |
| 2015 | 561 |
| 2016 | 1,058 |
| 2017 | 1,008 |
| 2018 | 1,397 |
| 2019 | 1,669 |
| 2020 | 1,510 |
| 2021 | 1,127 |
| 2022 | 1,187 |
| 2023 | 1,262 |
| 2024 | 1,875 |
| 2025 | 2,125 |
| 2026 | 1,392 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Doryx Mpc (Doxycycline Hyclate)
2024 spending
$244K
Beneficiaries
141
244 claims
Per beneficiary
$1,729
$19.26 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $64,227 |
| 2021 | $43,583 |
| 2022 | $37,447 |
| 2023 | $145,512 |
| 2024 | $243,799 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Doxycycline Prophylaxis to Prevent Sexually Transmitted Infections in Women.
Stewart J, Oware K, Donnell D, et al. · N Engl J Med 2023 · Comparative Study, Randomized Controlled Trial
- Comparative evaluation of demineralized freeze-dried bone allograft with and without doxycycline hyclate loaded proniosomal gel in the treatment of class II furcation defects: a randomized controlled trial.
Biradar V, Mody D, Kolte AP, et al. · Clin Oral Investig 2025 · Randomized Controlled Trial, Comparative Study
- Tolerability of doxycycline monohydrate salt vs. chloroquine-proguanil in malaria chemoprophylaxis.
Pagès F, Boutin JP, Meynard JB, et al. · Trop Med Int Health 2002 · Clinical Trial, Randomized Controlled Trial
- Local prolonged release of antibiotic for prevention of sternal wound infections postcardiac surgery-A novel technology.
Kachel E, Moshkovitz Y, Sternik L, et al. · J Card Surg 2020 · Multicenter Study, Randomized Controlled Trial
- Subantimicrobial-dose doxycycline treatment increases serum cholesterol efflux capacity from macrophages.
Salminen A, Pussinen PJ, Payne JB, et al. · Inflamm Res 2013 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- The effect of medication cost transparency alerts on prescriber behavior.
Monsen CB, Liao JM, Gaster B, et al. · J Am Med Inform Assoc 2019 · Randomized Controlled Trial
Sponsor: Mayne Pharma · Also marketed as Doryx
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.